GlaxoSmithKline (LON:GSK) PT Set at GBX 1,942 by HSBC

GlaxoSmithKline (LON:GSK) has been given a GBX 1,942 ($25.38) price objective by equities researchers at HSBC in a report released on Tuesday, Borsen Zeitung reports. The brokerage presently has a “buy” rating on the stock. HSBC’s price objective would suggest a potential upside of 17.67% from the stock’s previous close.

Other analysts have also issued research reports about the stock. Credit Suisse Group initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Monday, May 20th. They issued a “neutral” rating and a $336.00 price target on the stock. Bryan, Garnier & Co lowered their price target on shares of GlaxoSmithKline from GBX 1,710 ($22.34) to GBX 1,660 ($21.69) and set a “neutral” rating on the stock in a research report on Thursday, May 2nd. Morgan Stanley initiated coverage on shares of in a research report on Monday, June 17th. They issued an “equal weight” rating and a GBX 215 ($2.81) price target on the stock. Liberum Capital reissued a “hold” rating on shares of Daily Mail and General Trust P L C in a research report on Tuesday, July 2nd. Finally, Jefferies Financial Group reissued a “buy” rating and issued a C$15.00 price target on shares of Aphria in a research report on Friday, May 24th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of GBX 1,536.87 ($20.08).

LON GSK opened at GBX 1,650.40 ($21.57) on Tuesday. The company has a 50 day simple moving average of GBX 1,591.48. GlaxoSmithKline has a 12-month low of GBX 1,408.80 ($18.41) and a 12-month high of GBX 1,658 ($21.66). The company has a current ratio of 0.72, a quick ratio of 0.45 and a debt-to-equity ratio of 942.07. The company has a market capitalization of $82.83 billion and a price-to-earnings ratio of 21.02.

In other news, insider Manvinder Singh Banga bought 458 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The shares were acquired at an average price of GBX 1,568 ($20.49) per share, with a total value of £7,181.44 ($9,383.82). Insiders have purchased a total of 482 shares of company stock worth $755,935 in the last ninety days.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

See Also: What is Elliott Wave theory?

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with's FREE daily email newsletter.